Analysis of random recombination between human MDR1 and mouse Mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system

Molecular Pharmacology

Volumn 54, Issue 4, 1998, Pages 623-630

  Shoshani, Tzipora ^a   Zhang, Shudong ^a,b   Dey, Saibal ^a   Pastan, Ira ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; COLCHICINE; CYCLOSPORIN A; GLYCOPROTEIN P; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; VALSPODAR; VERAPAMIL;

ARTICLE; CANCER CHEMOTHERAPY; DNA LIBRARY; DNA SEQUENCE; DRUG BINDING; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; MUTAGENESIS; NONHUMAN; PHOTOAFFINITY LABELING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMBINANT DNA TECHNOLOGY;

ANIMALS; AZIDES; BIOLOGICAL TRANSPORT; DNA, COMPLEMENTARY; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; KB CELLS; MICE; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; PRAZOSIN; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; SENSITIVITY AND SPECIFICITY; TETRAHYDROFOLATE DEHYDROGENASE; TRANSFECTION;

EID: 0031783756     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Abbaszadegan RA, Foley NE, Gleason-Guzman MC, and Dalton WS (1996) Resistance to the chemosensitizer, verapamil, in a multidrug resistant (MDR) human multiple myeloma cell line. Int J Cancer 66:506-514.
2. Akiyama S, Fojo A, Hanover JA, Pastan I, and Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11:117-126.
3. Aran JM, Gottesman MM, and Pastan I (1994) Drug-selected coexpression of human glycocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA 91:3176-3180.
4. Boscoboinik D, Debanne MT, Stafford AR, Yung CY, Gupta RS, and Epand RM (1990) Dimerization of the P-glycoprotein in membranes. Biochim Biophys Res Commun 185:284-290.
5. Bruggemann EP, Currier SJ, Gottesman MM, and Pastan I (1992) Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 267:21020-21026.
6. Cardarelli CO, Aksentijevich I, Pastan I, and Gottesman MM (1995) Differential effect of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 55:1086-1091.
7. Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou J-P, Dumontet C, and Sikic BI (1997) Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype and resistance to cyclosporins. J Biol Chem 272:5974-5982.
8. Crameri A, Cwirla S, and Stemmer WPC (1996) Construction and evolution of antibody-phage libraries by DNA shuffling. Nat Med 2:100-103.
9. Crameri A, Dawes G, Rodriguez E, Silver S, and Stemmer WPC (1997) Molecular evolution of an arsenate detoxification pathway by DNA shuffling. Nat Biotechnol 15:436-438.
10. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TE, and Salmon SE (1989) Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424.
11. Dey S, Ramachandra M, Pastan I, Gottesman MM, and Ambudkar SV. (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94:10594-10599.
12. Germann UA, Pastan I, and Gottesman MM (1993) P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 4:63-76.
13. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, and Gottesman MM (1996) Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271:1708-1716.
14. Gottesman MM, and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
15. Greenberger LM (1993) Major photoaffnity drug labeling sites for iodoarylazidoprazosin in P-glycoprotein are within or immediately C-terminal to transmembrane domain-6 and domain-12. J Biol Chem 268:11417-11425.
16. Hamada H, and Tsuruo T (1986) Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83:7785-7789.
17. 939/941. Biochemistry 33:5041-5048.
18. Loo T W, and Clarke DM (1993) Functional consequences of phenylalanine mutations in the predicted transmembrane domains of P-glycoprotein. J Biol Chem 268:19965-19972.
19. Loo TW, and Clarke DM (1994) Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33:14049-14057.
20. 2+. Nucleic Acids Res 23:3067-3068.
21. Ma JF, Grant G, and Melera PW (1997) Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. Mol Pharmacol 51:922-930.
22. Mechetner EB, and Roninson IB (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89:5824-5828.
23. Mechetner EB, Schott B, Morse BS, Stein WD, Druley T, Davis KA, Tsuruo T, and Roninson IB (1997) P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA 94:12908-12913.
24. Metz MZ, Matsumoto L, Winters KA, Doroshow JH, and Kane SE (1996) Bicistronic and two-gene retroviral vectors for using MDR 1 as a selectable marker and a therapeutic gene. Virology 217:230-241.
25. Morris DI, Greenberger LM, Bruggemann EP, Cardarelli CO, Gottesman MM, Pastan I, and Seamon KB (1994) Localization of the labeling sites of forskolin to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Mol Pharmacol 46:329-337.
26. Schinkel AH, Arceci RJ, Smit JJM, Wagenaar E, Baas F, Dolle M, Tsuruo T, Mechetner EB, Roninson IB, and Borst P (1993) Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer 55:478-484.
27. Solary E, Caillot D, Chauffert B, Casasnovas R, Dumas M, Maynadie D, and Guy H (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730-1736.
28. Stein WD, Cardarelli C, Pastan I, and Gottesman MM (1994) Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45:763-772.
29. Stemmer WPC (1994a) DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution. Proc Natl Acad Sci USA 91:10747-10751.
30. Stemmer WPC (1994b) Rapid evolution of protein in vitro by DNA shuffling. Nature 370:389-391.
31. Tang-Wai DF, Kajiji S, DiCapua F, Graaf D, Roninson IB, and Gros P (1995) Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34:32-39.
32. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, and Sikic B (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1624-1634.
33. Yang CP, Cohen D, Greenberger LM, Hsu SI, and Horwitz SB (1990) Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 265:10282-10288.
34. Zhang S, Sugimoto Y, Shoshani T, Pastan I, and Gottesman MM (1998) pHaMDRDHFR bicistronic expression system for mutational analysis of P-glycoprotein. Methods Enzymol 292:474-480.